Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I0DL
|
|||
| Former ID |
DNC000178
|
|||
| Drug Name |
Alpha 1-PI
|
|||
| Synonyms |
Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alpha-1 antitrypsin deficiency [ICD-11: 5C5A; ICD-10: E88.0, M79.3; ICD-9: 273.4] | Approved | [1], [2] | |
| Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Withdrawn from market | [3], [4] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H27NO2
|
|||
| Canonical SMILES |
CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3
|
|||
| InChI |
1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
|
|||
| InChIKey |
UYNVMODNBIQBMV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 23210-56-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4725773, 8152332, 14752941, 24262973, 26751765, 29215029, 29222812, 47811044, 47960032, 49698431, 50016323, 50104451, 50104452, 53788156, 57321942, 77542351, 81041086, 85213187, 85787500, 90341159, 92308801, 96024756, 103856535, 103983044, 104304238, 118313765, 123121346, 124749897, 124886924, 124960908, 125345551, 126645206, 129438974, 134339686, 134339687, 135048478, 135697523, 137004977, 142433824, 144204466, 152034593, 162174615, 162222110, 163414206, 164786771, 170465791, 170485605, 172913925, 178102121, 179150197
|
|||
| ChEBI ID |
CHEBI:93829
|
|||
| SuperDrug ATC ID |
C04AX28
|
|||
| SuperDrug CAS ID |
cas=023210562
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003666) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5472). | |||
| REF 4 | Effects of the novel 5-hydroxytryptamine reuptake inhibitor indalpine and ethanol on psychomotor performance. Arzneimittelforschung. 1988 Jan;38(1):98-102. | |||
| REF 5 | NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250. | |||
| REF 6 | Elastase inhibitors. J Soc Biol. 2001;195(2):143-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.